A Journey of Three Decades
Since 1987, MEBO Group has transformed the treatment of burns and chronic wounds, establishing a new paradigm in regenerative medicine.
Mission, Vision and Values
The principles that guide every decision at MEBO Group and have allowed us to transform the lives of millions of patients for over three decades.
Mission
Provide regenerative therapeutic solutions that alleviate the suffering of patients with burns and chronic wounds, promoting the natural healing of skin without invasive surgery.
- Global treatment accessibility
- Certified pharmaceutical quality
- Continuous professional training
Vision
To be the global benchmark in regenerative medicine, bringing Regenerative Medicine to every corner of the world where there is a patient who needs to regenerate their skin.
- Expansion to 100+ countries
- Leadership in regenerative research
- Global standard of care
Values
Scientific innovation, respect for life, academic integrity and unwavering commitment to patient well-being in every decision.
- Evidence-based science
- Respect for human dignity
- Integrity in all research
- Commitment to the patient
MEBO Group Milestones
Nearly four decades of continuous innovation, global expansion, and commitment to regenerative science.
APEC Host Committee Co-Chair
Kevin Xu serves as Co-Chair of the APEC 2023 Host Committee in San Francisco, with MEBO as an official enterprise partner. At the summit he attends Peruvian President Dina Boluarte's private dinner ahead of the APEC handover to Peru. Presence reaches more than 70 countries.
United States
APEC 2023
PeruPeru in Action
"Life Regeneration Initiative" launches with Peruvian non-profit ANIQUEM to care for children with burn injuries; the Latin America Forum is hosted in Lima; the Peruvian edition of MEBO Ointment is included in the official APEC 2024 gift bag.
Peru
APEC 2024Silver Healing at the UN
At the Clinton Global Initiative Health Working Group during UN General Assembly week, Kevin Xu launches 'Silver Healing' — equitable community wound care for elderly patients across 28 countries (2025–2028). Eighth consecutive year at EWMA Barcelona; regenerative medicine webinars under the APEC framework begin across Latin America.
UN
APEC 2025Hospitalar Debut in Brazil
MEBO showcases its regenerative medicine technologies for the first time at Hospitalar in São Paulo, Brazil. The Latin America regenerative medical technology seminar series continues — four online seminars held to date.
BrazilCNIPA Patent
A significant formulation and mechanism patent is granted by the China National Intellectual Property Administration.
European Patent
A European patent is obtained for therapeutic applications in diabetic foot ulcer management and healing.
Australian Patent
The intellectual property portfolio expands with an Australian patent for diabetic foot ulcer management.
70+ Countries
Presence grows to more than 70 countries across Asia, the Middle East, Africa, Europe and Latin America — millions of patients treated.
WHO First-Aid Recognition
MEBO Ointment is officially acknowledged by the World Health Organization as a first-aid medicine for burns.
The Definitive Monograph
"Burns Regenerative Medicine and Therapy" is published by Swiss academic press Karger, standardizing the technology for clinical audiences worldwide.
New Markets & Gulf Partnership
Launches in Indonesia, the Philippines and New Zealand; strategic partnership formed with Gulf Pharmaceutical Industries (Julphar).
Established
Professor Rongxiang Xu founds the Guangming Burn and Ulcer Research Institute in Beijing — MEBO is born.
First New Drug Certificate
MEBO Ointment receives China's first new drug certificate for traditional Chinese medicine in burn treatment; the therapy wins the State Technological Invention Award of China.
First International Relief Mission
MEBO Ointment is deployed to treat victims of the catastrophic gas explosion in Bangkok, Thailand — its first major international disaster-relief application.
Nationwide Adoption
Selected by China's Ministry of Health among the 10 Major Medical Technologies for nationwide promotion.
Production Base Launched
MEBO's first medicine is approved and patented; Shantou MEBO launches as the group's production base.
U.S. Patent & First Overseas Markets
The burn ointment formula is granted a U.S. patent; the therapy launches in Syria, the UAE, South Korea and Thailand.
MEBO Around the World
MEBO Group’s companies and branches in China and overseas — dual headquarters, nine overseas branches, and a multi-national manufacturing network.
Certifications and Recognitions
MEBO's commitment to quality is backed by rigorous international certifications.
Manufacturing certified to both China GMP and Australia TGA GMP guidelines
Patents granted in China, the United States, Europe, and Japan
New drug certification from China's National Medical Products Administration
Registered as a drug in more than 40 countries worldwide
Discover the Science Behind MEBO
Learn how Regenerative Medicine is transforming the treatment of burns and chronic wounds worldwide.
Explore Regenerative Medicine